← Human Trials & Peer-Reviewed Studies
Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis
Plain-language guide to PMID 36410666 (2023): open-label randomized controlled trial study of Teriparatide in 86 women, osteoporosis and bone density.
Key Facts
- PMID
- 36410666
- Journal
- Bone
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Ganapathy A et al. (4 authors)
- DOI
- 10.1016/j.bone.2022.116618
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.
To evaluate the effects of cyclic vs daily teriparatide treatment (TPTD) on volumetric bone mineral density (vBMD) and bone strength at the hip and spine in women who were previously untreated.
Who Took Part
The study group was 86 women.
PubMed tags the participants as women only.
During a 2-year extension, women in the daily TPTD group were switched to alendronate (ALN) and those in the cyclic TPTD group continued on cyclic TPTD (without any ALN).
QCT images were acquired at baseline, 2-years (n = 54) and 4-years (n = 35) and analyzed for volumetric integral, cortical and trabecular bone mineral density (vBMD) and bone strength (by finite element analysis) at the hip and spine.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.
Being open-label, the Teriparatide study did not mask who received what.
A time span of 2 years appears in the methods.
What Was Measured
PubMed files the paper under topics including Alendronate, Bone Density, Bone Density Conservation Agents, Osteoporosis, Osteoporosis, Postmenopausal, Postmenopause and Teriparatide.
Author keywords: Bone strength, QCT and Volumetric bone mineral density.
What This Means in Plain Language
The paper is a randomized and open-label study of Teriparatide in 86 women in people with osteoporosis and bone density over 2 years.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Bone), a journal based in United States.
More context: the Teriparatide compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.